Martha Leen, MD
Ophthalmology · Silverdale, WANPI 1093716458
Payments from drug & device makers
Across 74 payments — averaging $30.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$595
- AbbVie$587
- Sight Sciences, Inc.$155
- Apellis Pharmaceuticals, Inc.$118
- Bausch & Lomb Americas Inc.$103
- Bausch & Lomb, A Division Of Bausch Health US, LLC$93
- plus $600 from 14 others
What the payments were for
- Speaking & faculty fees$1004%
- Food & beverage$2,15096%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $595 |
| AbbVie(2 entities) | 19 | $587 |
| Sight Sciences, Inc. | 4 | $155 |
| Apellis Pharmaceuticals, Inc. | 1 | $118 |
| Bausch & Lomb Americas Inc. | 6 | $103 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $93 |
| Thea Pharma Inc. | 4 | $87 |
| Tarsus Pharmaceuticals, Inc. | 3 | $85 |
| Oyster Point Pharma, Inc. | 3 | $71 |
| Sun Pharmaceutical Industries Inc. | 3 | $70 |
| Biotissue Holdings Inc. | 2 | $48 |
| Harrow Eye, LLC | 2 | $42 |
| NEW World Medical,inc. | 2 | $42 |
| Carl Zeiss Meditec USA, Inc. | 1 | $29 |
| Dompe US, Inc. | 1 | $28 |
| Kala Pharmaceuticals, Inc. | 1 | $25 |
| Akorn, Inc. | 1 | $21 |
| Rxsight Inc | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ PanOptix UV IOL$150
- AcrySof IQ VIVITY$150
- Clareon$150
- XEN$100
How this compares
$2,250 in reported general payments places this provider in the 70th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 80 | $38,446 |
| RestasisCyclosporine | 25 | $35,335 |
| LumiganBimatoprost | 36 | $22,619 |
| VyzultaLatanoprostene Bunod | 24 | $15,742 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $13,136 |
| Travoprost | 91 | $12,609 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $10,489 |
| Latanoprost | 705 | $9,731 |
| Brinzolamide | 53 | $8,944 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $8,869 |
| Prednisolone Acetate | 194 | $8,369 |
| Timolol Maleate | 308 | $8,261 |
| Alphagan PBrimonidine Tartrate | 13 | $7,351 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 287 | $5,431 |
| Brimonidine Tartrate | 195 | $5,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $587 | $74,17489 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $14 | $51,582102 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $103 | $15,74224 claims |
| AlconSimbrinza | $595 | $10,48932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Silverdale
- Todd SchneidermanSilverdale$602K
- David SpinakSilverdale$351K
- Elizabeth MartinSilverdale$90K
- Paul KremerSilverdale$42K
- Robert WirthlinSpokane$2.4M
- Laura PerimanSeattle$1.9M
- Sheldon CowenSeattle$560K
- Todd KlesertBellevue$506K
- Jason JonesSpokane$386K
- Jay RuddPuyallup$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.